Company announced the publication of clinical data from a Phase 1/2 trial of TG-1101 (ublituximab), the Company’s novel glycoengineered
anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkins Lymphoma (NHL) or Chrionic Lymphocytic Leukemia (CLL) previously
exposed to rituximab. The data demonstrates single agent TG-1101 to be well tolerated with the most common adverse event observed being
grade 1/2 infusion related reactions (IRR), with no grade 3/4 IRR’s. TG-1101 monotherapy was active, with a 45% overall response rate (ORR)
observed among heavily pretreated patients with NHL and CLL including those who were refractory to prior CD-20 based therapy.
This clinical data, in my opinion published in the British Journal of Haematology is substantial news and the impetus that we need to finally propel the price of this
undervalued company. Long, Long and Long again.
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.